Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma.
The immune system plays a key role in preventing tumor formation by recognizing and destroying malignant cells. For over a century, researchers have attempted to harness the immune response as a cancer treatment, although this approach has only recently achieved clinical success. Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and is associated with cigarette smoking, alcohol consumption, betel nut use, and human papillomavirus infection. Unfortunately, worldwide mortality from HNSCC remains high, partially due to limits on therapy secondary to the significant morbidity associated with current treatments. Therefore, immunotherapeutic approaches to HNSCC treatment are attractive for their potential to reduce morbidity while improving survival. However, the application of immunotherapies to this disease has been challenging because HNSCC is profoundly immunosuppressive, resulting in decreased absolute lymphocyte counts, impaired natural killer cell function, reduced antigen-presenting cell function, and a tumor-permissive cytokine profile. Despite these challenges, numerous clinical trials testing the safety and efficacy of immunotherapeutic approaches to HNSCC treatment are currently underway, many of which have produced promising results. This review will summarize immunotherapeutic approaches to HNSCC that are currently undergoing clinical trials.
Division of Otolaryngology, Head and Neck Surgery, Department of Surgery, College of Medicine, The Pennsylvania State University, 500 University Drive, P.O. Box 850, Hershey, PA 17033, USA. dbann@hmc.psu.edu.|Institute for Personalized Medicine, College of Medicine, The Pennsylvania State University, Hershey, PA 17033, USA. dbann@hmc.psu.edu.
Darrin V
DV
Bann
Department of Otolaryngology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, MA 02114, USA. daniel_deschler@meei.harvard.edu.
Daniel G
DG
Deschler
Division of Otolaryngology, Head and Neck Surgery, Department of Surgery, College of Medicine, The Pennsylvania State University, 500 University Drive, P.O. Box 850, Hershey, PA 17033, USA. ngoyal1@hmc.psu.edu.
Neerav
N
Goyal
head and neck squamous cell carcinoma; immune checkpoint inhibitors; immunotherapy; monoclonal antibody; oncolytic viruses; tumor vaccine
N Engl J Med. 2015 Oct 22;373(17):1627-39
26412456
Clin Cancer Res. 2013 Mar 1;19(5):1126-38
23209031
Mol Ther. 2008 Sep;16(9):1637-42
18628758
Lancet. 2015 Nov 21;386(10008):2078-88
26386540
J Oncol. 2012;2012:542851
22481930
Semin Oncol. 2012 Jun;39(3):296-304
22595052
Nat Immunol. 2002 Nov;3(11):991-8
12407406
Ann Oncol. 2012 Jan;23(1):72-7
21464154
J Clin Oncol. 2008 Dec 20;26(36):5896-903
19029422
Proc R Soc Med. 1910;3(Surg Sect):1-48
19974799
Cancer Res. 2003 Sep 1;63(17):5595-600
14500400
Oral Oncol. 2012 Aug;48(8):678-85
22387210
Cancer Immunol Immunother. 2012 Sep;61(9):1395-405
22270713
Nature. 2014 Nov 27;515(7528):568-71
25428505
Nat Immunol. 2002 Feb;3(2):135-42
11812990
Curr Opin Immunol. 1997 Oct;9(5):684-93
9368778
Clin Otolaryngol Allied Sci. 2000 Apr;25(2):130-4
10816217
Clin Cancer Res. 2011 Nov 15;17(22):7164-73
22068656
Am J Clin Oncol. 2011 Apr;34(2):173-8
20539208
Nat Rev Clin Oncol. 2016 May;13(5):273-90
26977780
Ann Oncol. 2013 Jan;24(1):75-83
22858559
J Immunol. 2006 Jun 1;176(11):6434-42
16709800
Clin Cancer Res. 2009 Dec 1;15(23 ):7412-20
19934295
Eur J Cancer. 2014 Feb;50(3):496-505
24262587
Invest New Drugs. 2013 Oct;31(5):1207-16
23397499
Mol Ther. 2012 Apr;20(4):749-58
22186794
Cancer Immunol Immunother. 2013 Aug;62(8):1347-57
23685782
Int J Cancer. 2009 Aug 1;125(3):698-707
19431145
J Clin Oncol. 2012 Jun 10;30(17 ):2046-54
22547592
Vaccine. 2009 Jun 19;27(30):3975-83
19389451
Vaccine. 2006 Oct 30;24(42-43):6564-73
16837111
Anticancer Res. 2006 Mar-Apr;26(2A):873-84
16619482
Clin Cancer Res. 2014 Jul 15;20(14):3683-91
24807889
Neoplasia. 2013 Jul;15(7):805-14
23814492
Nature. 1970 Jul 11;227(5254):168-70
4316953
N Engl J Med. 2010 Aug 19;363(8):711-23
20525992
PLoS One. 2010 May 03;5(5):e10436
20454651
Cancer Med. 2013 Oct;2(5):662-73
24403232
Ann Oncol. 2016 Jun;27(6):984-97
26861598
Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):775-9
11448348
Trends Mol Med. 2014 Jun;20(6):332-42
24667139
Anticancer Res. 2004 Sep-Oct;24(5C):3295-301
15515424
Oral Oncol. 2014 May;50(5):498-505
24613543
J Immunother. 2007 Sep;30(6):624-33
17667526
Onco Targets Ther. 2014 Jun 12;7:1001-14
24959087
Invest New Drugs. 2014 Dec;32(6):1278-84
24894651
Clin Cancer Res. 2009 Sep 1;15(17):5323-37
19723653
Nat Rev Drug Discov. 2004 Jul;3(7):549-50
15272498
Oncoimmunology. 2015 Sep 2;5(3):e1088631
27141345
Jpn J Clin Oncol. 2014 Jan;44(1):9-12
24371262
BMC Med. 2016 May 05;14 :73
27151159
Eur J Immunol. 2007 Nov;37 Suppl 1:S34-45
17972343
Lancet Oncol. 2013 May;14(6):e218-28
23639322
J Clin Oncol. 2013 Jul 1;31(19):2396-403
23715567
Immunol Res. 2012 Dec;54(1-3):266-74
22454102
Cancer Immunol Immunother. 2015 Mar;64(3):367-79
25537079
Nat Med. 2013 Mar;19(3):329-36
23396206
Lancet Oncol. 2016 Jun;17(6):822-35
27132212
Oncotarget. 2016 Jun 7;7(23):33498-511
27172898
Dent Res J (Isfahan). 2012 Dec;9(Suppl 2):S192-6
23814582
Lancet Oncol. 2010 Jan;11(1):21-8
19897418
Nature. 2015 Jan 29;517(7536):576-82
25631445
Mol Ther. 2011 Oct;19(10):1913-22
21772252
Int Immunopharmacol. 2003 Aug;3(8):1073-81
12860164
J Clin Oncol. 2013 Jul 1;31(19):2413-20
23715572
Clin Cancer Res. 2012 Jan 15;18(2):499-509
22128302
Clin Cancer Res. 2014 Mar 1;20(5):1355-65
24520093
Int J Cancer Suppl. 1991;6:95-100
2066187
Clin Cancer Res. 2016 May 15;22(10):2342-50
26813357
Med Hypotheses. 2008;70(6):1186-92
18054441
Cancer Immunol Res. 2015 Oct;3(10 ):1148-57
26014098
BMC Med. 2013 Oct 22;11:227
24148310
Vaccine. 2010 Oct 8;28(43):7054-62
20708999
J Clin Oncol. 2014 Sep 20;32(27):2940-50
25154822
J Clin Oncol. 2011 Jul 1;29(19):2667-74
21632509
Mol Ther. 2015 Sep;23(9):1532-40
26073886
Int J Oncol. 2004 Apr;24(4):901-8
15010828
J Immunol. 1999 Jun 1;162(11):6934-41
10352316
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
21296855
Br J Cancer. 1990 Dec;62(6):1047-51
2257212
J Clin Oncol. 2011 Oct 1;29(28):3783-90
21900113
J Clin Oncol. 2005 Dec 1;23(34):8646-54
16314626
MAbs. 2009 Jan-Feb;1(1):41-8
20046573
N Engl J Med. 2008 Sep 11;359(11):1116-27
18784101
N Engl J Med. 2009 Nov 5;361(19):1838-47
19890126
Cancer Chemother Pharmacol. 2015 Apr;75(4):701-9
25627002
Scientifica (Cairo). 2013;2013:857519
24278787
Am J Clin Oncol. 2015 Feb;38(1):108-18
23608828
Br J Pharmacol. 2012 Apr;165(7):2089-99
22029729
Am Health Drug Benefits. 2015 Aug;8(Spec Issue):16
26380607
Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):261-6
22171012
PLoS One. 2016 Feb 29;11(2):e0148764
26928328
PLoS One. 2013;8(2):e47234
23408925
Int Immunol. 2015 Jan;27(1):3-10
25038057
Front Immunol. 2013 Mar 27;4:76
23543707
Oncologist. 2005 Oct;10(9):760-1
16249358
Clin Cancer Res. 2008 Jan 1;14(1):169-77
18172268